Literature DB >> 28082090

Endothelial dysfunction and abnormal vascular structure are simultaneously present in patients with heart failure with preserved ejection fraction.

Shinji Kishimoto1, Masato Kajikawa1, Tatsuya Maruhashi1, Yumiko Iwamoto1, Takeshi Matsumoto1, Akimichi Iwamoto1, Nozomu Oda1, Shogo Matsui1, Takayuki Hidaka1, Yasuki Kihara1, Kazuaki Chayama2, Chikara Goto3, Yoshiki Aibara4, Ayumu Nakashima5, Kensuke Noma4, Yukihito Higashi6.   

Abstract

BACKGROUND: Endothelial dysfunction and abnormal vascular structure may be involved in the pathogenesis of chronic heart failure (HF). The purpose of this study was to evaluate simultaneously vascular function and vascular structure in patients with heart failure with preserved ejection fraction (HFpEF).
METHODS: We measured flow-mediated vasodilatation (FMD) and nitroglycerine-induced vasodilation as indices of vascular function and intima-media thickness (IMT) as an index of vascular structure of the brachial artery in 41 patients with HFpEF (23 men and 18 women; mean age, 66±12yr) and 165 patients without HF (95 men and 70 women; mean age, 54±16yr).
RESULTS: FMD was significantly smaller in patients with HFpEF than in patients without HF (2.9±2.1% versus 4.6±2.7%, P=0.0002). Nitroglycerine-induced vasodilation was significantly smaller in patients with HFpEF than in patients without HF (9.3±4.1% versus 12.9±4.9%, P<0.0001). Brachial artery IMT was significantly larger in patients with HFpEF than in patients without HF (0.35±0.06mm versus 0.31±0.07mm, P=0.0002). After adjustment for age, sex, hypertension, dyslipidemia, and diabetes mellitus, the associations remained significant between HFpEF and FMD (odds ratio, 0.79; 95% confidence interval, 0.66-0.92; P=0.0032), nitroglycerine-induced vasodilation (odds ratio, 0.88; 95% confidence interval, 0.80-0.96; P=0.0039), and brachial artery IMT (odds ratio, 1.08; 95% confidence interval, 1.01-1.17; P=0.033).
CONCLUSIONS: These findings suggest that both endothelial dysfunction and abnormal vascular structure may contribute to the pathogenesis and maintenance of HFpEF. Endothelial function and vascular structure may be potential therapeutic targets for HFpEF.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endothelial function; Flow-mediated vasodilatation; Heart failure with preserved ejection fraction; Intima-media thickness; Vascular structure

Mesh:

Substances:

Year:  2017        PMID: 28082090     DOI: 10.1016/j.ijcard.2017.01.024

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

1.  Cardiovascular responses to rhythmic handgrip exercise in heart failure with preserved ejection fraction.

Authors:  Stephen M Ratchford; Heather L Clifton; D Taylor La Salle; Ryan M Broxterman; Joshua F Lee; John J Ryan; Paul N Hopkins; Josephine B Wright; Joel D Trinity; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-09-17

Review 2.  Skeletal muscle abnormalities in heart failure with preserved ejection fraction.

Authors:  Matthew Anderson Md; Clifton Forrest Parrott; Mark J Haykowsky Ph D; Peter H Brubaker Ph D; Fan Ye Md; Bharathi Upadhya Md
Journal:  Heart Fail Rev       Date:  2022-03-30       Impact factor: 4.214

3.  Locomotor Muscle Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Michael A Francisco; Joshua F Lee; Zachary Barrett-O'Keefe; H Jonathan Groot; Stephen M Ratchford; Kanokwan Bunsawat; Jeremy K Alpenglow; John J Ryan; Jose N Nativi; Russell S Richardson; D Walter Wray
Journal:  Hypertension       Date:  2021-11-01       Impact factor: 10.190

Review 4.  Pathophysiology of Exercise Intolerance and Its Treatment With Exercise-Based Cardiac Rehabilitation in Heart Failure With Preserved Ejection Fraction.

Authors:  Wesley J Tucker; Siddhartha S Angadi; Mark J Haykowsky; Michael D Nelson; Satyam Sarma; Corey R Tomczak
Journal:  J Cardiopulm Rehabil Prev       Date:  2020-01       Impact factor: 3.646

Review 5.  Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.

Authors:  Andreas B Gevaert; Katrien Lemmens; Christiaan J Vrints; Emeline M Van Craenenbroeck
Journal:  Oxid Med Cell Longev       Date:  2017-06-19       Impact factor: 6.543

6.  Integrating Pharmacokinetics Study, Network Analysis, and Experimental Validation to Uncover the Mechanism of Qiliqiangxin Capsule Against Chronic Heart Failure.

Authors:  Yu Zhang; Mingdan Zhu; Fugeng Zhang; Shaoqiang Zhang; Wuxun Du; Xuefeng Xiao
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

7.  Tai Chi exercise and functional electrical stimulation of lower limb muscles for rehabilitation in older adults with chronic systolic heart failure: a non-randomized clinical trial.

Authors:  Yi Hao; Long Zhang; Zhenhua Zhang; Lin Chen; Ning He; Shuai Zhu
Journal:  Braz J Med Biol Res       Date:  2019-11-25       Impact factor: 2.590

8.  Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus.

Authors:  Saverio Tremamunno; Antonio De Vita; Angelo Villano; Veronica Melita; Gessica Ingrasciotta; Eleonora Ruscio; Monica Filice; Antonio Bisignani; Salvatore Emanuele Ravenna; Linda Tartaglione; Gaetano Emanuele Rizzo; Mauro Di Leo; Tamara Felici; Dario Pitocco; Gaetano Antonio Lanza
Journal:  Diabetes Metab Res Rev       Date:  2021-07-14       Impact factor: 8.128

9.  Clinical Significance of Skin Autofluorescence in Patients With Type 2 Diabetes Mellitus With Chronic Heart Failure.

Authors:  Takashi Hitsumoto
Journal:  Cardiol Res       Date:  2018-04-25

10.  Hematocrit, hemoglobin and red blood cells are associated with vascular function and vascular structure in men.

Authors:  Shinji Kishimoto; Tatsuya Maruhashi; Masato Kajikawa; Shogo Matsui; Haruki Hashimoto; Yuji Takaeko; Takahiro Harada; Takayuki Yamaji; Yiming Han; Yasuki Kihara; Kazuaki Chayama; Chikara Goto; Farina Mohamad Yusoff; Ayumu Nakashima; Yukihito Higashi
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.